ArticleJournal of bioenergetics and biomembranes2025
NSUN2 contributes to the RB malignant progression and Glycolysis by mediating the m5C methylation modification of HKDC1.
Article in Journal of bioenergetics and biomembranes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Computational prioritization of candidate TCDD-associated targets in retinoblastoma using network toxicology and transcriptomic analysis.Frontiers in genetics · 2026Article
- RNA Methylation in Cancer Metabolism: from Mechanisms to Therapeutic Opportunities.International journal of biological sciences · 2026Review
- The Role of NSUN Family Genes in m5C Methylation and Diseases.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoblastoma (RB) is a malignant neoplasm originating from photoreceptor precursor cells that is common in children under 3 years of age. NOP2/Sun RNA methyltransferase family member 2 (NSUN2) is a major methyltransferase that catalyzes mammalian mRNA 5-methylcytosine (m5C) modification and has been implicated in a variety of diseases, but its mechanism in RB is still incomplete. NSUN2 was up-regulated in RB and was associated with the poor survival of patients. Silencing NSUN2 blocked the malignant behaviors of RB cells. In Y79 cells, the differentially expressed genes (DEGs) after knocking down NSUN2 were mainly concentrated in the glycolytic pathway from the GSE214685 dataset, and NSUN2 down-regulation restrained the glycolysis of RB cells. What's more, the m5C modification and mRNA stability of hexokinase domain component 1 (HKDC1) were mediated by NSUN2 and Y-box binding protein 1 (YBX1). Mechanically, NSUN2 promoted RB malignant behaviors and glycolysis in vitro via HKDC1 and accelerated tumor growth in vivo. Our study put forward a new mechanism to regulate RB progression, namely, NSUN2 and YBX1 synergistically promote malignant progression and glycolysis of RB by mediating HKDC1 m5C modification.
Indexed as
Identifiers
40423890What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.